Literature DB >> 23507739

Lung cancer: OPTIMAL results for erlotinib in NSCLC.

Lisa Hutchinson.   

Abstract

Entities:  

Year:  2013        PMID： 23507739     DOI： 10.1038/nrclinonc.2013.45

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).

Authors:  G Chen; J Feng; C Zhou; Y-L Wu; X-Q Liu; C Wang; S Zhang; J Wang; S Zhou; S Ren; S Lu; L Zhang; C-P Hu; C Hu; Y Luo; L Chen; M Ye; J Huang; X Zhi; Y Zhang; Q Xiu; J Ma; L Zhang; C You
Journal:  Ann Oncol       Date:  2013-03-01       Impact factor: 32.976
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.